Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value
$11.37−0.13 (-1.09%)
Close on Nov 13, 2026Market cap $695.13MP/E –Yield –
Janux Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Janux Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -428.7%. For fiscal 2025 it was -1136.3%, against -651.6% the year before. The highest annual figure on record is -651.6% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1136.3% | −484.6 |
| FY2024 | Dec 31, 2024 | -651.6% | +69.6 |
| FY2023 | Dec 31, 2023 | -721.2% | +11.0 |
| FY2022 | Dec 31, 2022 | -732.2% | +166.1 |
| FY2021 | Dec 31, 2021 | -898.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -232.2% | +6159.4 |
| Q2 FY2026 | Jun 30, 2026 | -214.0% | −147.0 |
| Q1 FY2026 | Mar 31, 2026 | -652.6% | +526.3 |
| Q3 FY2025 | Sep 30, 2025 | -243.1% | +234.6 |
| Q3 FY2024 | Sep 30, 2024 | -6391.6% | −5932.0 |
| Q2 FY2024 | Jun 30, 2024 | -67.0% | +1589.4 |
| Q1 FY2024 | Mar 31, 2024 | -1178.9% | −326.4 |
| Q4 FY2023 | Dec 31, 2023 | -477.8% | +86.9 |
| Q3 FY2023 | Sep 30, 2023 | -459.6% | +461.3 |
| Q2 FY2023 | Jun 30, 2023 | -1656.4% | −942.3 |
| Q1 FY2023 | Mar 31, 2023 | -852.5% | −8.6 |
| Q4 FY2022 | Dec 31, 2022 | -564.7% | +265.5 |
| Q3 FY2022 | Sep 30, 2022 | -920.9% | +8.0 |
| Q2 FY2022 | Jun 30, 2022 | -714.1% | +573.5 |
| Q1 FY2022 | Mar 31, 2022 | -843.9% | −242.9 |
| Q4 FY2021 | Dec 31, 2021 | -830.2% | – |
| Q3 FY2021 | Sep 30, 2021 | -928.9% | – |
| Q2 FY2021 | Jun 30, 2021 | -1287.6% | – |
| Q1 FY2021 | Mar 31, 2021 | -601.1% | – |
See a number that looks wrong?